Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
NRIX Income Before Tax
Profit after all operating and non-operating items but before income tax.
Nurix Therapeutics, Inc.NASDAQ: NRIX
Income Before Tax · Q3 FY2026 · quarter ended Aug 2026
Income before tax turns positive
Q3 FY2026 income before tax was $563.41M, compared with -$86.42M a year earlier. Trailing-twelve-month income before tax was $308.21M.
Context
- Income before tax amounted to 314.0% of revenue in FY2025, down 40.4 pp from a year earlier.
- Income before tax grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near $563.41M or moves back toward the trailing-twelve-month quarterly average of $77.05M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (263.7M) USD
- Year-over-year change
- -36.4%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-11-30 | (263.7M) | -36.4% |
| FY2024 | 2024-11-30 | (193.3M) | -34.3% |
| FY2023 | 2023-11-30 | (143.95M) | +20.2% |
| FY2022 | 2022-11-30 | (180.36M) | -54.1% |
| FY2021 | 2021-11-30 | (117.06M) | — |
Income Before Tax vs competitors
How NRIX compares with its peers on the latest reported figures
- NRIX's LTM Aug 2026 income before tax of $308.21M is the highest of the 8 companies compared; the peer median is -$243.25M.
- Its year-over-year change of +226.3% is the highest of 8, against a peer median of -8.9%.
- Income before tax amounts to 43.9% of revenue for NRIX, versus a peer median of 285.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $308.21M | +226.3% | — | 43.9% | |
| LTM Mar 2026 | $121.97M | +219.9% | — | 40.7% | |
| LTM Mar 2026 | -$103.68M | -0.5% | — | 297.4% | |
| LTM Sep 2026 | -$208.05M | -107.2% | — | — | |
| LTM Mar 2026 | -$243.25M | +26.6% | — | 112.0% | |
| LTM Mar 2026 | -$294.49M | -63.9% | — | 411.1% | |
| LTM Jun 2026 | -$299.87M | -8.9% | — | 285.6% | |
| LTM Jun 2026 | -$1.77B | -117.6% | — | — | |
| Peer median (excluding NRIX) | -$243.25M | -8.9% | — | 285.6% | |
Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Revenue | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Cost of Revenue | 116.43M | 184.5M | 189.15M | 221.63M | 18.86M |
| Gross Profit | (86.68M) | (145.87M) | (112.16M) | (167.08M) | 65.12M |
| Gross Margin | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| Research & Development | 116.43M | 184.5M | 189.15M | 221.63M | 308.16M |
| Selling, General & Admin | 31.2M | 38M | 42.9M | 45.94M | 52.74M |
| Operating Expenses | 31.2M | 38M | 42.9M | 45.94M | 350.79M |
| Depreciation & Amortization | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| EBITDA | (110.98M) | (169.55M) | (130.29M) | (176.87M) | (244.84M) |
| EBITDA Margin | -373.0% | -438.9% | -169.2% | -324.2% | -291.5% |
| Operating Income | (117.89M) | (183.87M) | (155.06M) | (213.03M) | (285.67M) |
| Operating Margin | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Interest Income | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Income Before Tax | (117.06M) | (180.36M) | (143.95M) | (193.3M) | (263.7M) |
| Pre-Tax Margin | -393.5% | -466.9% | -187.0% | -354.4% | -314.0% |
| Income Tax Expense | 131K | 0 | 0 | 270K | 760K |
| Net Income | (117.19M) | (180.36M) | (143.95M) | (193.57M) | (264.46M) |
| Net Margin | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| EPS (Basic) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| EPS (Diluted) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| Weighted Avg Shares | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
| Weighted Avg Shares (Diluted) | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.